BrainVectis receives funding to support gene therapy for Huntington's and Alzheimer's disease

Parisian-based BrainVectis, a spin-off of Inserm, has received €1m in funding from private investors, which will be used to complete preclinical pharmacological tests.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news